BRAFV600E-mutant melanoma presenting with cardiac involvement

Douglas B. Johnson*, Jeffrey A. Sosman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Melanoma is an aggressive skin cancer with historically limited treatment options. Approximately 50% of melanomas harbor BRAFV600 mutations. This report describes a 32-year-old man with metastatic BRAFV600- mutant melanoma who presented with cardiac involvement. Recently developed treatment options for patients with BRAF-mutant melanoma include BRAF inhibitors (vemurafenib, dabrafenib), MEK inhibitors (trametinib), and immune-based therapeutics (interleukin-2 or ipilimumab), but the most effective strategy for first-line therapy is heavily debated. Opinions vary for treatment selection, but the general consensus recommends immune-based therapies initially for asymptomatic patients with low-volume disease, and BRAF inhibitors for those with highly symptomatic or rapidly progressing disease. In this case, melanoma with cardiac involvement, although clinically uncommon, presents challenging management decisions.

Original languageEnglish (US)
Pages (from-to)611-615
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number5
StatePublished - 2014

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'BRAFV600E-mutant melanoma presenting with cardiac involvement'. Together they form a unique fingerprint.

Cite this